<source id="xgbgn"><menu id="xgbgn"></menu></source>

            0431-81311122

            國際前沿科技

            Stem Cell Reports:干細胞移植可治療II型糖尿病

            2015-03-23

            來源:生物谷 2015-03-22

              
            2015年3月22日訊 /生物谷BIOON/ --近日,來自加拿大的科學家在國際期刊Stem Cell Reports在線發表了他們的最新研究成果,他們發現胰腺前體細胞移植對于II型糖尿病治療具有良好效果,與糖尿病治療藥物聯合使用,治療效果更加明顯,這項研究表明基于干細胞技術的治療方法或許是治療II型糖尿病的一種可行方法。
             
            人類胚胎干細胞誘導的胰腺前體細胞能夠有效逆轉I型糖尿病動物模型的高血糖癥,但其對于II型糖尿病的治療作用仍未有報道。研究人員通過高脂喂養SCID-beige小鼠構建了患有II型糖尿病的免疫缺陷模型,研究發現在進行干細胞移植后,高脂飲食刺激不會影響胰腺前體細胞向具有胰島素分泌功能的胰腺細胞的分化成熟過程,并且這種細胞治療方法能夠改善接受了干細胞移植的小鼠在高脂飲食喂養下的葡萄糖耐受性,但其治療效應要在干細胞移植24周后才會顯現。
             
            單純依靠干細胞移植并不能完全改善飲食誘導的高血糖癥和肥胖,因此研究人員對另一批II型糖尿病小鼠模型進行了胰腺前體細胞移植和糖尿病治療藥物的聯合治療,實驗結果表明,選取的三種糖尿病治療藥物結合干細胞移植均能快速改善小鼠體重,并且干細胞移植與西格列汀或二甲雙胍聯用在移植后12周就可改善小鼠高血糖癥。
             
            這項研究表明基于干細胞技術的治療方法或許是治療糖尿病的一種有效選擇,與糖尿病治療藥物聯用會起到更好的治療效果。(生物谷Bioon.com)
             
            本文系生物谷原創編譯整理。歡迎轉載!
             
             
             
            Treating Diet-Induced Diabetes and Obesity with Human Embryonic Stem Cell-Derived Pancreatic Progenitor Cells and Antidiabetic Drugs
             
            Jennifer E. Bruin, Nelly Saber, Natalie Braun, Jessica K. Fox, Majid Mojibian, Ali Asadi, Campbell Drohan, Shannon O'Dwyer, Diana S. Rosman-Balzer, Victoria A. Swiss, Alireza Rezania, Timothy J. Kieffer
             
            Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2 diabetes was generated by high-fat diet (HFD) feeding in SCID-beige mice. Exposure to HFDs did not impact the maturation of macroencapsulated pancreatic progenitor cells into glucose-responsive insulin-secreting cells following transplantation, and the cell therapy improved glucose tolerance in HFD-fed transplant recipients after 24 weeks. However, since diet-induced hyperglycemia and obesity were not fully ameliorated by transplantation alone, a second cohort of HFD-fed mice was treated with pancreatic progenitor cells combined with one of three antidiabetic drugs. All combination therapies rapidly improved body weight and co-treatment with either sitagliptin or metformin improved hyperglycemia after only 12 weeks. Therefore, a stem cell-based therapy may be effective for treating type 2 diabetes, particularly in combination with antidiabetic drugs.
             


            地址:吉林省長春市高新技術產業開發區錦湖大路1357(E)寶孚大廈4006室 電話:0431-81311122
            版權所有:長春力太生物科技有限公司 吉ICP備14006071號-1

            建站技術支持長春龐智科技

            天堂Av无码AV一区二区三区_免费AV毛片不卡无码_精品美国A片一级_亚洲福利网入口久久
                    <source id="xgbgn"><menu id="xgbgn"></menu></source>